In this open-label, phase I dose-escalation trial in newly diagnosed patients with GBM, the MTD of afatinib was 30 mg/day in combination with RT and TMZ (regimen M; methylated MGMT promoter), and 40 mg/day in combination with RT (regimen U; unmethylated MGMT promoter). This evidence concerns the gene MGMT and glioblastoma.